Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-2.00 Insider Own5.85% Shs Outstand24.77M Perf Week7.55%
Market Cap172.89M Forward P/E- EPS next Y-1.76 Insider Trans0.34% Shs Float23.32M Perf Month46.64%
Income-38.72M PEG- EPS next Q-0.47 Inst Own66.72% Short Float3.34% Perf Quarter67.39%
Sales3.57M P/S48.43 EPS this Y59.67% Inst Trans25.73% Short Ratio2.77 Perf Half Y69.01%
Book/sh0.89 P/B7.83 EPS next Y21.08% ROA-73.87% Short Interest0.78M Perf Year199.57%
Cash/sh2.18 P/C3.20 EPS next 5Y- ROE-206.79% 52W Range2.19 - 7.50 Perf YTD39.32%
Dividend Est.- P/FCF- EPS past 5Y19.64% ROI-148.47% 52W High-6.93% Beta1.46
Dividend TTM- Quick Ratio6.81 Sales past 5Y-55.72% Gross Margin2.30% 52W Low218.72% ATR (14)0.50
Dividend Ex-Date- Current Ratio6.81 EPS Y/Y TTM88.64% Oper. Margin-1316.62% RSI (14)70.13 Volatility9.75% 9.56%
Employees57 Debt/Eq0.26 Sales Y/Y TTM-17.90% Profit Margin-1085.29% Recom1.00 Target Price21.50
Option/ShortYes / Yes LT Debt/Eq0.18 EPS Q/Q67.68% Payout- Rel Volume0.86 Prev Close6.70
Sales Surprise- EPS Surprise9.99% Sales Q/Q- EarningsNov 13 BMO Avg Volume280.89K Price6.98
SMA2027.87% SMA5033.04% SMA20063.53% Trades Volume242,876 Change4.18%
Date Action Analyst Rating Change Price Target Change
Nov-11-20Upgrade Cantor Fitzgerald Neutral → Overweight $4
Sep-18-20Initiated B. Riley FBR Buy $5
Feb-10-20Initiated SVB Leerink Outperform $6
Dec-10-19Resumed Cantor Fitzgerald Neutral $2 → $4
Aug-15-19Downgrade Maxim Group Buy → Hold
Aug-12-19Downgrade Cantor Fitzgerald Overweight → Neutral $29 → $2
Jul-26-19Downgrade Mizuho Buy → Neutral $17 → $4
Jun-27-19Initiated Mizuho Buy
Oct-12-18Initiated Mizuho Buy $17
Jun-05-18Initiated Seaport Global Securities Buy $29
Feb-15-24 05:52AM
Feb-01-24 04:05PM
Jan-08-24 07:30AM
Dec-15-23 07:30AM
07:30AM Loading…
Nov-27-23 07:30AM
Nov-17-23 10:09AM
Nov-14-23 04:29AM
Nov-13-23 12:23PM
Nov-01-23 07:30AM
Sep-26-23 07:30AM
Sep-12-23 12:48PM
07:30AM Loading…
Sep-07-23 07:30AM
Aug-30-23 07:30AM
Aug-11-23 07:41AM
Aug-08-23 08:27AM
Jul-28-23 07:30AM
Jul-19-23 08:30AM
Jul-07-23 08:30AM
Jul-03-23 08:45AM
Jun-09-23 07:30AM
Jun-01-23 07:30AM
May-30-23 08:00AM
May-25-23 12:27AM
May-22-23 07:30AM
May-16-23 09:00AM
08:15AM Loading…
May-13-23 08:15AM
May-11-23 07:54AM
Apr-18-23 07:15AM
Apr-10-23 07:30AM
Mar-31-23 06:22AM
Mar-29-23 07:30AM
Mar-24-23 07:30AM
Mar-16-23 07:30AM
Mar-14-23 07:30AM
Nov-14-22 07:30AM
Nov-08-22 02:28PM
Nov-03-22 12:44PM
Oct-19-22 07:30AM
Oct-04-22 07:30AM
Sep-22-22 07:30AM
Sep-13-22 07:30AM
Sep-08-22 08:48AM
Aug-11-22 07:30AM
Jul-20-22 07:30AM
Jun-24-22 10:08AM
Jun-13-22 01:27PM
Jun-10-22 03:30PM
Jun-08-22 01:21PM
Jun-06-22 02:04PM
Jun-01-22 02:25PM
May-31-22 02:27PM
May-25-22 02:29PM
May-23-22 03:32PM
May-19-22 03:02PM
May-18-22 03:12PM
May-17-22 09:27AM
May-13-22 07:30AM
May-12-22 02:47PM
May-11-22 02:28PM
May-10-22 02:36PM
May-06-22 03:48PM
May-04-22 07:30AM
May-03-22 07:00AM
Apr-29-22 09:00AM
Apr-19-22 10:51AM
Mar-31-22 07:30AM
Mar-28-22 11:20AM
Mar-14-22 07:30AM
Jan-25-22 10:00AM
Dec-22-21 07:30AM
Dec-17-21 09:00AM
Dec-16-21 04:01PM
Dec-02-21 07:25AM
Nov-19-21 10:00AM
Nov-18-21 07:30AM
Nov-17-21 07:30AM
Nov-16-21 07:30AM
Nov-15-21 07:45AM
Oct-21-21 07:30AM
Oct-13-21 07:30AM
Oct-12-21 07:30AM
Sep-21-21 04:01PM
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Seshadri VishwasChief Executive OfficerFeb 06Buy4.3920,00087,800528,260Feb 07 08:30 AM
Alvino MarkDirectorJan 17Sale5.117,08436,19962,816Jan 22 04:30 PM
Seshadri VishwasChief Executive OfficerSep 27Buy4.0720,00081,400521,731Sep 29 07:30 AM
Charles Faith L.DirectorSep 27Sale4.918,33040,92470,773Sep 29 04:30 PM
Alland LeilaDirectorSep 27Sale3.907,24628,27071,857Sep 29 04:30 PM
Alvino MarkDirectorSep 27Sale3.916,31624,72469,900Sep 29 04:30 PM
Silverstein Christine BerniDirectorSep 27Sale3.916,33024,72187,884Sep 29 04:30 PM
Amoroso MichaelDirectorSep 27Sale3.915,50821,542108,957Sep 29 04:30 PM
Amoroso MichaelDirectorSep 20Sale3.903271,275114,465Sep 22 04:05 PM
Vazzano Joseph WalterChief Financial OfficerSep 19Buy3.823,00011,458238,179Sep 20 09:00 AM
O'Malley Brendan M.SVP, General CounselSep 18Buy3.803,00011,400187,421Sep 19 09:00 AM
Amoroso MichaelDirectorJun 20Sale4.453381,504114,792Jun 21 04:05 PM
Alvino MarkDirectorApr 25Sale3.258872,88317,527May 05 04:05 PM
Amoroso MichaelDirectorMar 20Sale2.3326862456,441Mar 21 05:13 PM
Amoroso MichaelDirectorMar 03Sale2.381,0022,38556,709Mar 03 07:06 PM